Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03157089 · ClinicalTrials.gov registry record · Phase 2
Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT03157089 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 24 participants.
The verdict
NCT03157089, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
The main objective is to assess the efficacy of afatinib in combination with pembrolizumab, as measured by objective response (OR) in patients with locally advanced or metastatic squamous NSCLC who progressed during or after first line platinum-based treatment. The secondary objectives are to confirm the RP2D, assess the safety profile, and the secondary measures of clinical efficacy including disease control (DC), duration of objective response (DoR), progression-free survival (PFS), overall survival (OS), and tumour shrinkage.
Interventions
- DRUG pembrolizumab
- DRUG Afatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2017-11-02 |
| Est. Completion | 2020-01-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03157089
The ClinicalTrials.gov registry entry for NCT03157089 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pembrolizumab is the first listed.
NCT03157089 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03157089 about?
NCT03157089 is a clinical study titled "Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung". The main objective is to assess the efficacy of afatinib in combination with pembrolizumab, as measured by objective response (OR) in patients with locally advanced or metastatic squamous NSCLC who progressed during or after first line platinum-based treatment. The secondary objectives are to confi...
What is the current status of trial NCT03157089?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2017-11-02. Estimated completion is 2020-01-13.
What interventions are being tested in trial NCT03157089?
The interventions under investigation include: pembrolizumab (DRUG), Afatinib (DRUG).
Who is sponsoring clinical trial NCT03157089?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.